Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Citi
Fuji
Medtronic
Cipla
Queensland Health
Julphar
Fish and Richardson
Cantor Fitzgerald

Generated: February 19, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR GEMCITABINE HYDROCHLORIDE

« Back to Dashboard

Clinical Trials for Gemcitabine Hydrochloride

Trial ID Title Status Sponsor Phase Summary
NCT00001431 A Phase I Trial of Gemcitabine and Radiation in Locally Advanced Unresectable Cancer of the Pancreas Completed National Cancer Institute (NCI) Phase 1 Radiotherapy plus Single-Agent Chemotherapy/Radiosensitization. Involved-field irradiation using 4-15 MV photons; plus Gemcitabine, NSC-613327.
NCT00001449 A Phase I Study of Weekly Gemcitabine in Combination With Infusional Fluorodeoxyuridine and Oral Calcium Leucovorin in Adult Cancer Patients Completed National Cancer Institute (NCI) Phase 1 The purpose of this study is to determine the clinical toxicities associated with administering sequential dFdC as a one hour infusion followed by a continuous infusion of FUdR over 24 hours with low dose oral LV weekly for three weeks out of four.
NCT00002998 Gemcitabine and Cisplatin in Treating Patients With Metastatic Breast Cancer Completed National Cancer Institute (NCI) Phase 2 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of gemcitabine and cisplatin in treating patients with metastatic breast cancer that has not responded to systemic therapy.
NCT00002998 Gemcitabine and Cisplatin in Treating Patients With Metastatic Breast Cancer Completed Alliance for Clinical Trials in Oncology Phase 2 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of gemcitabine and cisplatin in treating patients with metastatic breast cancer that has not responded to systemic therapy.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Gemcitabine Hydrochloride

Condition Name

Condition Name for Gemcitabine Hydrochloride
Intervention Trials
Pancreatic Cancer 358
Lung Cancer 97
Breast Cancer 91
Bladder Cancer 85
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Gemcitabine Hydrochloride
Intervention Trials
Pancreatic Neoplasms 646
Carcinoma, Non-Small-Cell Lung 314
Lung Neoplasms 303
Adenocarcinoma 261
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Gemcitabine Hydrochloride

Trials by Country

Trials by Country for Gemcitabine Hydrochloride
Location Trials
United States 6,156
Italy 399
Canada 381
Spain 266
Germany 245
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Gemcitabine Hydrochloride
Location Trials
New York 326
California 305
Texas 293
Pennsylvania 261
Florida 252
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Gemcitabine Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Gemcitabine Hydrochloride
Clinical Trial Phase Trials
Phase 4 19
Phase 3 278
Phase 2/Phase 3 42
[disabled in preview] 1123
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Gemcitabine Hydrochloride
Clinical Trial Phase Trials
Completed 874
Recruiting 447
Terminated 203
[disabled in preview] 177
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Gemcitabine Hydrochloride

Sponsor Name

Sponsor Name for Gemcitabine Hydrochloride
Sponsor Trials
National Cancer Institute (NCI) 370
Eli Lilly and Company 160
M.D. Anderson Cancer Center 52
[disabled in preview] 52
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Gemcitabine Hydrochloride
Sponsor Trials
Other 2096
Industry 1032
NIH 379
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Deloitte
Teva
US Department of Justice
AstraZeneca
Accenture
Citi
US Army
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.